Insider Trading Alert - FR, BHB And DSCI Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 5, 2014, 98 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $85.00 to $13,664,800.00.

Highlighted Stocks Traded by Insiders:

First Industrial Realty (FR) - FREE Research Report

Duncan Bruce W, who is President and CEO at First Industrial Realty, sold 16,179 shares at $20.11 on Dec. 5, 2014. Following this transaction, the President and CEO owned 1.0 million shares meaning that the stake was reduced by 1.56% with the 16,179-share transaction.

The shares most recently traded at $19.97, down $0.14, or 0.7% since the insider transaction. Historical insider transactions for First Industrial Realty go as follows:

  • 4-Week # shares sold: 28,556
  • 12-Week # shares bought: 7,900
  • 12-Week # shares sold: 103,556
  • 24-Week # shares bought: 7,900
  • 24-Week # shares sold: 149,974

The average volume for First Industrial Realty has been 553,300 shares per day over the past 30 days. First Industrial Realty has a market cap of $2.2 billion and is part of the financial sector and real estate industry. Shares are up 14.56% year-to-date as of the close of trading on Thursday.

First Industrial Realty Trust Inc. is a real estate investment trust. The firm invests in the real estate markets of the United States. It makes investments in industrial properties. The firm owns, manages, acquires, sells, develops, and redevelops industrial real estate. The stock currently has a dividend yield of 2.05%. The company has a P/E ratio of 143.1. Currently, there are 3 analysts who rate First Industrial Realty a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FR - FREE

TheStreet Quant Ratings rates First Industrial Realty as a hold. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth and good cash flow from operations. However, as a counter to these strengths, we find that the company's profit margins have been poor overall. Get the full First Industrial Realty Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Bar Harbor Bankshares (BHB) - FREE Research Report

Murphy Joseph Michael, who is Director at Bar Harbor Bankshares, sold 150 shares at $30.50 on Dec. 5, 2014. Following this transaction, the Director owned 94,949 shares meaning that the stake was reduced by 0.16% with the 150-share transaction.

Simard Curtis C, who is President & CEO at Bar Harbor Bankshares, bought 200 shares at $30.50 on Dec. 5, 2014. Following this transaction, the President & CEO owned 3,395 shares meaning that the stake was boosted by 6.26% with the 200-share transaction.

The shares most recently traded at $31.25, up $0.75, or 2.4% since the insider transaction. Historical insider transactions for Bar Harbor Bankshares go as follows:

  • 4-Week # shares bought: 1,126
  • 4-Week # shares sold: 314
  • 12-Week # shares bought: 2,226
  • 12-Week # shares sold: 314
  • 24-Week # shares bought: 3,726
  • 24-Week # shares sold: 314

The average volume for Bar Harbor Bankshares has been 5,100 shares per day over the past 30 days. Bar Harbor Bankshares has a market cap of $180.8 million and is part of the financial sector and banking industry. Shares are up 14.78% year-to-date as of the close of trading on Thursday.

Bar Harbor Bankshares operates as the holding company for Bar Harbor Bank & Trust that provides various banking products and services in Maine. The stock currently has a dividend yield of 3.09%. The company has a P/E ratio of 12.2. Currently, there are no analysts who rate Bar Harbor Bankshares a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BHB - FREE

TheStreet Quant Ratings rates Bar Harbor Bankshares as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in stock price during the past year, growth in earnings per share, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Bar Harbor Bankshares Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Derma (DSCI) - FREE Research Report

Stafford C Richard, who is Director at Derma, sold 6,075 shares at $8.59 on Dec. 5, 2014. Following this transaction, the Director owned 30,250 shares meaning that the stake was reduced by 16.72% with the 6,075-share transaction.

The shares most recently traded at $8.69, up $0.10, or 1.15% since the insider transaction. Historical insider transactions for Derma go as follows:

  • 4-Week # shares bought: 3,750
  • 4-Week # shares sold: 11,898
  • 12-Week # shares bought: 3,750
  • 12-Week # shares sold: 11,898
  • 24-Week # shares bought: 3,750
  • 24-Week # shares sold: 11,898

The average volume for Derma has been 69,900 shares per day over the past 30 days. Derma has a market cap of $208.6 million and is part of the health care sector and health services industry. Shares are down 20.61% year-to-date as of the close of trading on Thursday.

Derma Sciences, Inc. operates as a tissue regeneration company in the wound care market. It operates in three segments: Advanced Wound Care, Traditional Wound Care, and Pharmaceutical Wound Care. Currently, there are 3 analysts who rate Derma a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DSCI - FREE

TheStreet Quant Ratings rates Derma as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income and generally disappointing historical performance in the stock itself. Get the full Derma Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Stocks Rally on Dovish Trump Tariff Comments

Stocks Rally on Dovish Trump Tariff Comments

Retailers Sink With Williams-Sonoma After Revenue Miss

Retailers Sink With Williams-Sonoma After Revenue Miss

Hormel's Jennie-O Recalls 91,388 Pounds of Turkey on Salmonella Fears

Hormel's Jennie-O Recalls 91,388 Pounds of Turkey on Salmonella Fears

Nvidia Shares Tanking as Analysts Cut Price Targets

Nvidia Shares Tanking as Analysts Cut Price Targets

Dow Futures Weaken Amid Tech Sector Concerns; Oil Rebounds on OPEC Cut Plans

Dow Futures Weaken Amid Tech Sector Concerns; Oil Rebounds on OPEC Cut Plans